TRENDS IN PRICES AND CONSUMPTION OF BRANDED AND GENERIC OR BIOSIMILAR ANTINEOPLASTIC MEDICINES USED FOR SOLID TUMORS TREATMENT IN THE RUSSIAN PHARMACEUTICAL MARKET
Survey on the Role of Comparative Efficacy Studies Required for Biosimilar Monoclonal Antibody Approval in Japan to Justify the Quality Attribute Differences Between Biosimilars and Their Reference Products Based on the Pharmaceuticals and Medical Devices Agency (PMDA) Assessments
Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD.
